George Abercrombie - Theravance Insider

Theravance Inc -- USA Stock  

USD 9.81  9.81  9,223,372,036,855%

Senior Vice President - Corporate Partnerships, Commercial

Mr. George B. Abercrombie is Senior Vice President Corporationrationrate Partnerships Commercial of the Company. Mr. George B. Abercrombie RPh MBA joined Innoviva Inc. in June 2014. Prior to joining Innoviva Mr. Abercrombie served as the President and Chief Executive Officer of HoffmannLa Roche Inc. from 2001 to 2009 where he was responsible for the US and Canadian business divisions. From 1993 to 2001 Mr. Abercrombie worked at Glaxo and its successor companies including as Senior Vice President of Commercial Operations for Glaxo Wellcome Inc. He is the Chairman of the Board of BioCryst Pharmaceuticals Inc. and also serves as a board member of numerous other healthcarerelated organizations including Project Hope and the North Carolina GlaxoSmithKline Foundation
Age: 60  President Since 2014  MBA    
Abercrombie holds an MBA from Harvard Business School and a BS from the University of North Carolina at Chapel Hill, School of Pharmacy.

Management Efficiency

The company has return on total asset (ROA) of 1.82 % which means that it generated profit of $1.82 on every $100 spent on asset. This is way below average.
The company currently holds 744.09 M in liabilities with Debt to Equity (D/E) ratio of 1.09 which is about average as compared to similar companies. Theravance Inc has Current Ratio of 19.44 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 2 records


Peter MillonesBooking Holdings Inc
David GouldenBooking Holdings Inc

Entity Summary

Theravance, Inc., a royalty management company, is focused on developing respiratory products. Theravance Inc (THRX) is traded on NASDAQ in USA. It is located in South San Francisco, CA and employs 13 people.

Did you try this?

Run Equity Forecasting Now

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
Hide  View All  NextLaunch Equity Forecasting
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Theravance Inc to your portfolio

Top Management

Theravance Inc Leadership Team
Catherine Friedman, Director
Michael Aguiar, CEO, MBA
Barbara Duncan, Director
Paul Pepe, Director
George Abercrombie, President, MBA
Patrick LePore, Director
James Tyree, Director
Eric dEsparbes, CFO
Terrence Kearney, Director
Michael Faerm, SVP, MBA
Theodore Witek, SVP, MBA
William Waltrip, Director

Stock Performance

Theravance Performance Indicators